| Primary |
| Chronic Lymphocytic Leukaemia |
29.0% |
| Non-hodgkin's Lymphoma |
17.9% |
| B-cell Lymphoma |
10.2% |
| Mantle Cell Lymphoma |
10.0% |
| Multiple Myeloma |
5.7% |
| Lymphoma |
5.4% |
| Prophylaxis |
4.2% |
| Hypertension |
2.9% |
| Product Used For Unknown Indication |
2.0% |
| Plasma Cell Myeloma |
1.9% |
| Diffuse Large B-cell Lymphoma |
1.5% |
| Premedication |
1.4% |
| Nausea |
1.1% |
| Constipation |
1.1% |
| Non-hodgkin's Lymphoma Unspecified Histology Indolent |
1.1% |
| Diabetes Mellitus |
1.0% |
| Hodgkin's Disease |
1.0% |
| Back Pain |
0.9% |
| Prophylaxis Of Nausea And Vomiting |
0.9% |
| Extranodal Marginal Zone B-cell Lymphoma (Malt Type) |
0.8% |
|
| Rash |
17.0% |
| Pyrexia |
12.5% |
| Pancytopenia |
7.3% |
| Thrombocytopenia |
6.3% |
| Neutropenia |
6.2% |
| Death |
5.1% |
| Extravasation |
4.8% |
| White Blood Cell Count Decreased |
4.8% |
| Platelet Count Decreased |
4.0% |
| Vomiting |
3.9% |
| Pneumonia |
3.6% |
| Infusion Site Extravasation |
3.3% |
| Febrile Neutropenia |
3.2% |
| Sepsis |
3.2% |
| Fatigue |
2.7% |
| Phlebitis |
2.6% |
| Stevens-johnson Syndrome |
2.5% |
| Herpes Zoster |
2.3% |
| Diarrhoea |
2.3% |
| Dyspnoea |
2.2% |
|
| Secondary |
| Mantle Cell Lymphoma |
15.5% |
| Chronic Lymphocytic Leukaemia |
12.5% |
| B-cell Lymphoma |
12.1% |
| Non-hodgkin's Lymphoma |
10.9% |
| Multiple Myeloma |
9.0% |
| Prophylaxis |
8.1% |
| Product Used For Unknown Indication |
5.0% |
| Nausea |
3.1% |
| Hypertension |
3.0% |
| Lymphoma |
3.0% |
| Plasma Cell Myeloma |
3.0% |
| Diabetes Mellitus |
2.4% |
| Premedication |
2.2% |
| Chronic Obstructive Pulmonary Disease |
1.6% |
| Non-hodgkin's Lymphoma Unspecified Histology Indolent |
1.6% |
| Prophylaxis Of Nausea And Vomiting |
1.6% |
| Osteoarthritis |
1.4% |
| Pain |
1.4% |
| B-cell Small Lymphocytic Lymphoma |
1.3% |
| Insomnia |
1.3% |
|
| White Blood Cell Count Decreased |
9.7% |
| Pancytopenia |
8.6% |
| Pyrexia |
7.8% |
| Vomiting |
7.8% |
| Rash |
7.1% |
| Pneumonia |
5.6% |
| Platelet Count Decreased |
5.2% |
| Febrile Neutropenia |
4.8% |
| Nausea |
4.1% |
| Neutropenia |
4.1% |
| Syncope |
4.1% |
| Urinary Tract Infection |
4.1% |
| Vasculitis |
4.1% |
| Multiple Myeloma |
3.7% |
| Thrombocytopenia |
3.7% |
| Atrial Fibrillation |
3.3% |
| Renal Failure Acute |
3.3% |
| Death |
3.0% |
| Herpes Zoster |
3.0% |
| Infusion Site Extravasation |
3.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
38.4% |
| B-cell Lymphoma |
15.7% |
| Drug Use For Unknown Indication |
15.7% |
| Chronic Lymphocytic Leukaemia |
6.5% |
| B-cell Lymphoma Recurrent |
4.2% |
| Multiple Myeloma |
4.2% |
| Diffuse Large B-cell Lymphoma |
2.8% |
| Idiopathic Thrombocytopenic Purpura |
1.9% |
| Lymphoma |
1.9% |
| Nausea |
1.9% |
| Non-hodgkin's Lymphoma |
0.9% |
| Pain |
0.9% |
| Plasma Cell Myeloma |
0.9% |
| Prophylaxis Of Nausea And Vomiting |
0.9% |
| Renal Impairment |
0.9% |
| Bone Pain |
0.5% |
| Breast Cancer |
0.5% |
| Chemotherapy |
0.5% |
| Chronic Lymphocytic Leukemia |
0.5% |
| Hordeolum |
0.5% |
|
| Progressive Multifocal Leukoencephalopathy |
11.5% |
| Erythema |
7.7% |
| Haemorrhagic Anaemia |
7.7% |
| Lobar Pneumonia |
7.7% |
| Multiple Myeloma |
7.7% |
| Bone Pain |
3.8% |
| Death |
3.8% |
| Disease Progression |
3.8% |
| Drug Ineffective |
3.8% |
| Dyspnoea |
3.8% |
| Effusion |
3.8% |
| Fatigue |
3.8% |
| Febrile Neutropenia |
3.8% |
| Fibrosis |
3.8% |
| Mental Status Changes |
3.8% |
| Myelodysplastic Syndrome |
3.8% |
| Neoplasm |
3.8% |
| Non-hodgkin's Lymphoma |
3.8% |
| Pancreatitis |
3.8% |
| Performance Status Decreased |
3.8% |
|
| Interacting |
| Chronic Lymphocytic Leukaemia |
100.0% |
|
|
